What KCell Biosciences does

KCell Biosciences is a privately held joint venture between WSG (Korea) and Thousand Oaks Biopharmaceuticals (USA), headquartered in Busan, South Korea. The company is the first in Korea to establish large-scale mass-production capacity for serum-free and chemically defined cell culture media, serving global biopharmaceutical companies with a portfolio spanning customized media for recombinant protein production (CHO fed-batch, perfusion, and transient transfection variants), basal media (DMEM, RPMI 1640, MEM, Ham's F-12, and others), supplements and buffers, fetal bovine serum, cell freezing media, and growth factors, plus specialized media for stem cells (iPSC), immune cells (NK), and vaccines (Vero, MDCK, HEK293, insect, diploid, and veterinary lines). Its underlying technology includes proprietary CHO cell subtypes optimized for high-yield antibody and recombinant protein expression, achieving 3-6 g/L in 14-day fed-batch processes and >3.0 g/L in transient transfection, with industry-leading 30-45 day lead times for custom media manufacturing and comprehensive documentation supporting regulatory filings.

The company's business model is hybrid, combining product revenue from direct B2B sales of catalog media products with service revenue from contract manufacturing, cell line development, and mammalian transient transfection services. Pricing is quote-based and not publicly disclosed; customers engage through a formal product inquiry system with options for end-user, R&D institute, academic, and distributor business types, supported by a multi-region distribution footprint covering Korea (via parent WSG), China (via affiliate K1 Fluid Technology), and the United States (via the Thousand Oaks Biopharmaceuticals JV relationship). KCell holds ISO 14001 and ISO 45001 certifications and targets four primary customer segments: biopharmaceutical companies (primary), cellular agriculture / cultured meat producers, R&D institutes and academia, and distribution partners.

The company operates a relatively small commercial footprint relative to global bioprocess media leaders such as Cytiva, Thermo Fisher, and Sartorius, but occupies a defensible mid-market niche in Asia with capabilities spanning from sequence to commercialization for cell line development and integrated upstream bioprocess solutions. No public revenue, headcount, or funding data is disclosed in the available sources, and the company has no disclosed M&A, regulatory enforcement actions, leadership changes, or recent funding rounds in the input data.

Name

KCell Biosciences

Legal name

KCell Biosciences

Website

https://k-cell.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

KCell Biosciences is a Korea-based joint venture (WSG Korea × Thousand Oaks Biopharmaceuticals USA) that develops and manufactures serum-free, chemically defined cell culture media and provides cell line development and transient transfection services to global biopharmaceutical companies, cellular agriculture firms, and research institutions.

Ownership category

akta.pro rank

Product category

Cell Culture Media

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• Cell culture media
• Bioprocess services
• Transient transfection
• Cell line development
• Serum-free media

Headquarters

HQ city

Busan

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Cell Culture Media Products: Sale of serum-free chemically defined cell culture media products including CHO cell media, basal media, feed, supplements, and specialized media for various applications (recombinant proteins, stem cells, immune cells, vaccines). Products available in dry powder and liquid forms with customizable specifications.
2. Contract Manufacturing Services: Contract manufacturing services for culture media formulations including media formulation customization, formula component modifications (glutamine, sodium pyruvate, phenol red, sodium bicarbonate), medium form customization (dry powder or liquid), and packaging specifications.
3. Cell Line Development Services: Stable cell line development service including molecular cloning of gene sequences into expression plasmids, media optimization, and high-yield single cell clones. Service includes optional process scale-up from 2-15L bioreactor development through tech transfer.
4. Transient Transfection Services: Mammalian transient transfection services for protein production ranging from milligrams to grams, including vector construction, transient transfection, fed-batch expression, product harvest and testing (HPLC, ELISA, Fortebio), and optional protein purification.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

KCell Biosciences manufactures and sells serum-free, chemically defined cell culture media (CHO, iPSC, NK, Vero, MDCK, HEK293, basal media, and supplements) and provides contract development and manufacturing services including custom media formulation and manufacturing, stable CHO cell line development, and mammalian transient transfection services for biopharmaceutical and cellular agriculture customers.

Product overview

KCell Biosciences is a joint venture between WSG (Korea) and Thousand Oaks Biopharmaceuticals (USA), and the first in Korea to establish mass-production capacity of serum-free and chemically defined cell culture media. The company offers a comprehensive portfolio of cell culture media products and bioprocessing services. The product lineup includes: (1) Customized Cell Culture Media for Recombinant Protein Production (CHO Cell Media in Fed-batch, Perfusion, and Transient Transfection variants), Stem Cells (iPSC Medium), Immune Cells (NK Cell Medium), and Vaccines (Vero Cell Media, MDCK Cell Media, HEK293 Cell Media, Insect Cell Media, Diploid Cell Media, BD004 Media, and animal vaccine cell media including ST, MDBK, PK-15, BHK-21, and AM LSM 598); (2) Basal Cell Culture Media (DMEM, DMEM/F12, MEM, RPMI 1640, Ham's F-12, M199, IMDM, Leibovitz's L-15) along with Supplements and Buffers (PBS, HBSS, EBSS, PF-68, Glucose Solution, L-Glutamine, HT Concentrate, Trace Elements, Feed B); (3) Supplements including Fetal Bovine Serum (FBS) with multiple treatments, Cell Freezing Media (A, B, C for different applications including regenerative medicine), and Growth Factors; and (4) Customized Contract Services including Custom Media Manufacturing (Powder & Liquid), Media Formulation Development, Cell Line Development, and Mammalian Transient Transfection Platform (CHO and HEK293 systems). All products support the biopharmaceutical and cellular agriculture industries with animal component-free, protein-free, and chemically defined formulations.

Differentiator

Problem solved

Functional benefit

Products and services

• CHO Cell Media Platform (Fed-batch, Perfusion, Transient Transfection) Animal component-free, chemically defined media for CHO cells in suspension supporting high-density proliferation and high protein yield in fed-batch, perfusion, and transient transfection processes; intended for biopharmaceutical customers producing recombinant proteins and antibodies.
• iPSC Medium Xeno-free and feeder-free medium for human pluripotent stem cells (PSCs), extensively tested to maintain pluripotency; for stem cell research and regenerative medicine customers.
• NK Cell Medium Xeno-free medium for ex vivo expansion of human Natural Killer lymphocytes without feeder cells, maintaining CD56+/CD16+/CD3- surface marker expression; for immune cell therapy developers.
• Vaccine Cell Culture Media (Vero, MDCK, HEK293, Insect, Diploid, BD004, and veterinary lines ST, MDBK, PK-15, BHK-21, AM LSM 598) Animal component-free, protein-free, chemically defined media for Vero, MDCK, HEK293, insect, diploid and additional cell lines used in human and veterinary vaccine virus expression and recombinant protein production; supports serum-free high-density culture in spinner flask, sheet, or spherical microcarrier processes.
• Basal Cell Culture Media (DMEM, DMEM/F12, MEM, RPMI 1640, Ham's F-12, M199, IMDM, Leibovitz's L-15) Standard mammalian cell culture basal media formulations supporting growth of primary fibroblasts, neurons, HeLa, HEK293, COS-7, immune cells, and high-density and CO2-independent applications; available in various modifications (high/low glucose, with/without L-glutamine, phenol red, sodium pyruvate, NaHCO3, HEPES).
• Supplements and Buffers (PBS, HBSS, EBSS, PF-68, Glucose, L-Glutamine, HT Concentrate, Trace Elements, Feed B) Buffers, salt solutions, and feed supplements for improving cell culture efficiency, cell density, and process performance across basal and serum-free media applications.
• Fetal Bovine Serum (FBS) High-quality Fetal Bovine Serum with rigorous quality control, full Certificate of Analysis, and guaranteed traceability; available with Heat Inactivation and Gamma Irradiation treatment options for cell culture customers.
• Cell Freezing Media (A, B, C) Ready-to-use, serum-free cell freezing media that do not require a programmable freezer; supports long-term preservation at -80 degrees C or in liquid nitrogen, with variant C designed for regenerative medicine research on ES and iPS cells.
• Growth Factors Serum proteins and growth factors supporting cell culture applications across KCell's media platforms.
• Custom Media Manufacturing (Powder and Liquid) Contract manufacturing services for cell culture media with industry-leading 30-45 day lead time, flexible dry powder capacity for seamless scale-up, lot-to-lot consistency, and customization options for formula components (e.g., glutamine, sodium pyruvate, phenol red, sodium bicarbonate), medium form (dry powder or liquid), and packaging specifications; sample testing scale of 100-200 L.
• Media Formulation Development Custom development and optimization of cell culture media formulations, including preparation of customer-provided formulations, modification of public formulations, and proprietary KCell formulations.
• Cell Line Development Service Stable cell line development delivering high-yield cell clones for antibodies and recombinant proteins using proprietary CHO cell subtypes. Includes molecular cloning of gene sequences into expression plasmids, media optimization, single cell clone selection, stability testing, and optional process scale-up (2-15 L bioreactor) with tech transfer. Achieves 3-6 g/L protein yield in 14-day fed-batch processes, delivered within 3-5 months, with single cell imaging and cell growth rate documentation for regulatory filing.
• Mammalian Transient Transfection Service (CHO and HEK293 Systems) Contract mammalian transient expression service using CHO and HEK293 suspension cells, including vector construction, transient transfection, fed-batch expression, product harvest, optional protein purification, and testing (HPLC, ELISA, Fortebio). CHO system achieves greater than 3.0 g/L titer; HEK293 systems achieve 1.0 g/L titer; protein expression detectable as early as 2-3 days post-transfection; medium volume range of 40-2,000 mL; delivery in 2-3 weeks after contract signing.

Quantifiable outcome

• 130+ contracted projects successfully delivered
• +5 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Three partnerships are on record, tiered core and minor.

• WSGcoreStrategic or Co-development PartnerKCell Biosciences is the synergy-perfecting joint venture between WSG (Korea) and Thousand Oaks Biopharmaceuticals (USA). WSG is the Korean parent/affiliate company, positioned in close proximity to customers in Korea. Together, the partnership combines Korean manufacturing capabilities with US biopharmaceutical expertise.
• Thousand Oaks BiopharmaceuticalscoreStrategic or Co-development PartnerKCell Biosciences is a joint venture between WSG Korea and Thousand Oaks Biopharmaceuticals USA. Thousand Oaks Biopharmaceuticals brings expertise in integrated ADC CRDMO solutions and AI-driven platforms, while KCell provides serum-free cell culture media manufacturing capabilities. The partnership enables global pharmaceutical client support through combined technological strengths.
• K1 Fluid TechnologyminorOthersChina-based affiliate of WSG group (www.wsg-china.com), positioned to serve Chinese market alongside KCell Biosciences and WSG Korea operations.

Scale indicators11 records

Recent moves1 record

Expansion highlights6 records

Direct peers

• FUJIFILM Irvine Scientific: Specialized manufacturer of cell culture media for biopharma, cell therapy, and regenerative medicine. Direct overlap with KCell's serum-free media portfolio including CHO, iPSC, and immune cell media, and competes head-to-head in custom media manufacturing.
• CellGenix: Supplies GMP-grade raw materials and cell culture media for cell and gene therapy manufacturing. Direct competitor in immune cell (NK, T-cell) and stem cell media used in cell therapy manufacturing, with a stronger GMP focus than KCell.
• STEMCELL Technologies: Specializes in cell culture media, reagents, and tools for stem cell research, regenerative medicine, and immune cell therapy. Direct competitor in iPSC, NK cell, and cell freezing media segments where KCell is also active.

Broad incumbents

• Thermo Fisher Scientific (Gibco): Operates the Gibco brand, the world's largest portfolio of cell culture media, supplements, and reagents. Competes with KCell across CHO, HEK293, Vero, iPSC, and immune cell media, and offers comprehensive CDMO services through its Patheon network.
• Sartorius: Supplies bioprocess solutions including cell culture media, bioreactors, and filtration products. Competes with KCell in upstream bioprocessing and offers integrated platform solutions for biopharmaceutical manufacturing.
• Lonza: Global CDMO leader offering cell culture media and process development services alongside large-scale biologics manufacturing. Overlaps with KCell in upstream bioprocessing services and CHO/HEK293-based process development.
• Corning Life Sciences: Provides cell culture media, sera, and bioprocess containers used in biopharmaceutical manufacturing. Competes with KCell in basal media and supplements including FBS and classical formulations (DMEM, RPMI, MEM).
• Merck KGaA (Life Science): Provides EX-CELL, Cellvento, and other cell culture media brands plus a major biopharma CDMO business. Competes with KCell across mammalian cell culture media and provides complementary CDMO services in biologics manufacturing.
• Cytiva: Global leader in cell culture media (HyClone), bioprocessing equipment, and CDMO services. Cytiva is the dominant incumbent serving biopharmaceutical companies with serum-free media for CHO, HEK293, and other cell lines, directly competing with KCell's core offerings.

Regional players

• Samsung Biologics: Korea's largest biopharmaceutical CDMO offering commercial-scale mammalian cell culture manufacturing. While not a direct media competitor, Samsung is a key Korean-market customer/prospect for cell line development and process development services that KCell targets domestically.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kcell-10565

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KCell Biosciences